🇺🇸 Atorvastatin-omeprazole in United States
4 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 22 April 2025 – 22 April 2026
- Total reports: 4
Most-reported reactions
- Asthenia — 1 report (25%)
- Blood Sodium Decreased — 1 report (25%)
- Grand Mal Convulsion — 1 report (25%)
- Malaise — 1 report (25%)
Other Cardiovascular approved in United States
Frequently asked questions
Is Atorvastatin-omeprazole approved in United States?
Atorvastatin-omeprazole does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Atorvastatin-omeprazole in United States?
Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec is the originator. The local marketing authorisation holder may differ — check the official source linked above.